Navigation Links
Trial aims to advance prenatal diagnosis of genetic defects
Date:8/21/2013

0 or so microarray analyses, the researchers aim to follow 300600 children born with genetic variances, for at least three years. (See below for more about microarray.)

"While the majority of abnormalities found with microarray are associated with known conditions, in many cases the full implications of findings are not well understood, and about 1.5 percent are unidentified. The goal is to fill in these knowledge gaps," said Dr. Wapner. "Ours is the only study of its kind that is identifying genetic variances in utero and following the kids over time to see how the abnormalities present and to gather as much clinical information about them as possible, such as the severity of problems and life expectancy."

"When we counsel parents now, we can give them only limited information, drawn from what we know about children who have undergone genetic testing. But these children often represent the severe end of the spectrum," said Dr. Wapner. "There might be people who, because they had no symptoms, were never identified as having a variance, limiting the prognostic information we are able to give parents."

NewYork-Presbyterian/Columbia is the primary recruitment center. The other centers participating in the study are: the Center for Fetal Medicine, Northwestern University, Cedars Sinai Medical Center, San Francisco Perinatal, Carnegie Hill Imaging, Montefiore Medical Center, Mount Sinai Medical Center, Lenox Hill, and North Shore LIJ.

A majority of the labs in the country that do prenatal microarray have agreed to refer patients to the website, where they will be able to self-enroll in the study. "We hope to capture almost all the available microarray data," said Dr. Wapner.

Website to Collect, Share Information in Real Time with Parents, Clinicians

Trial data will be collected and shared in real time with parents and clinicians via the website http://www
'/>"/>

Contact: Elizabeth Streich
eas2125@cumc.columbia.edu
212-305-3689
Columbia University Medical Center
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Ultrasound patch heals venous ulcers in human trial
2. UCLA stem cell gene therapy for sickle cell disease advances toward clinical trials
3. New sickle cell anemia therapy advances to Phase II clinical trials
4. Alios BioPharma initiates Phase 1 clinical trial for respiratory syncytial virus infection
5. Intermountain Medical Center reseachers develop new 3-D technology to treat atrial fibrillation
6. Elseviers Maturitas publishes clinical guide on endometrial assessment in postmenopausal women
7. Ecology, economy and management of an agro-industrial Amazon frontier
8. FDA approves Phase II of stem cell trial for ALS led by U-Ms Dr. Eva Feldman
9. A trial to find out the effectiveness of biocides against Vespa velutina
10. Sea level rise: Jeopardy for terrestrial biodiversity on islands
11. Mummy CT scans show preindustrial hunter gatherers had clogged arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2015)... N.Y. , Aug. 19, 2015  VOXX ... that it has entered into a Definitive Agreement ... property, of iris authentication market leader EyeLock through ... VOXX will have a controlling interest in the ... subject to completion of due diligence.  Expanding on ...
(Date:8/17/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... mobile commerce market and creator of the Wocket® smart ... The new marketing campaign is being spearheaded by an ... ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ). ... driven marketing and brand awareness and has a client ...
(Date:8/12/2015)...  New research unveiled at Black Hat 2015 ... steal users, fingerprints. Information released today by HYPR ... on mobile devices, making the security of this ... mobile devices, HYPR Corp. recently released a biometric ... with strong cryptographic security. More information on this ...
Breaking Biology News(10 mins):VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 2VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 3VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 4VOXX International Corporation Signs Definitive Agreement To Acquire The Assets And A Controlling Interest Of Biometric Leader EyeLock 5NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... BGI the world,s largest genomic organization and Johns ... for the synthetic yeast project (SC2.0 PROJECT), an ambitious ... the yeast genome. This project was initiated by JHU ... In addition to the research collaboration of SC2.0 ...
... people in North America are afflicted with dystonia, a ... Patients with generalized dystonia grapple with involuntary muscle spasms ... sometimes painful postures. Although cognition, intelligence and life span ... impact on quality of life, as its victims frequently ...
... are most likely to become obese by examining their mothers, ... Montreal study published in the Archives of Pediatric and ... and is also influenced by a complex tangle of influencing ... improve the social and medical services we offer to mothers ...
Cached Biology News:BGI announces collaboration with Johns Hopkins University on synthetic yeast project 2BGI announces collaboration with Johns Hopkins University on synthetic yeast project 3University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3Future obesity may be predicted at 3.5 years of age 2
(Date:8/26/2015)... , Aug. 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of foodborne ... present at the Sidoti & Company Emerging Growth Conference ... be held at the New York Marriott Marquis. ... be available through the investor relations section of Roka ...
(Date:8/26/2015)...  Platform therapeutic company Symic Biomedical, Inc. ("Symic") ... Phase II SBIR grant from the National Institutes ... agent to reduce arteriovenous fistula (AVF) failures, a ... disease (ESRD) patients undergoing hemodialysis. The two-year project, ... Digestive and Kidney Diseases (NIDDK), will allow Symic ...
(Date:8/26/2015)... 26, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has been informed that ... wholly owned by Mr. Yuen Kam, chairman of the ... outstanding shares (the "Shares") of  Excellent China Healthcare Investment ...
(Date:8/26/2015)... ... , ... PRC Clinical, a Clinical Trial Management Expert CRO, will ... southern California. The Clinical Trial Management Expert CRO seeks to introduce more California-based sponsors ... , Stem Cell Meeting on the Mesa on October 7-9 ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Actavis Group, the,international generic pharmaceuticals company, today ... U.S. Food & Drug Administration to market,Fentanyl ... begin,immediately. Fentanyl Transdermal System is the ... 25, 50, 75 and 100 mcg/hour strengths.,Fentanyl ...
... (Euronext: AMT), a leader in the field of human ... results for the first,six months of 2007 on Wednesday, ... To discuss these results, the Company will conduct ... +31-800-949-4517 (toll free); US Dial In:,+1-866-291-4166 (toll free); UK ...
... Company confirms commercial expression levels of ... status of native Apo AI -, CALGARY, ... biotechnology company developing a portfolio of therapeutic,proteins for ... on July 12, 2007 announcing that the Company ...
Cached Biology Technology:Actavis Receives Approval of Fentanyl Transdermal System in the U.S. 2SemBioSys updates Apo AI development program 2SemBioSys updates Apo AI development program 3SemBioSys updates Apo AI development program 4
Porcine Coronary Artery Smooth Muscle Cells (PCASMC) (>500,000 cells)...
alpha-N-Catenin Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: